07 / 74 · 1:01 · Original AXON film
GLOW stack
The burned-in captions and transcript carry the scientific claims and their limitations. The visuals are conceptual illustrations, not validated molecular models or experimental images. The video has no voice or audio. The full explanation is visible on screen; optional accessible captions are available in the player.
Read every result in its study context. A cell experiment, animal model, exploratory analysis and controlled human trial answer different questions.
Prepared 05 November 2026. Regulatory status is jurisdiction- and date-specific. No claim of specialist review or exhaustive evidence coverage.
Transcript
GLOW | Combination claim
GLOW usually refers to a blend of GHK-Cu, BPC-157 and a product called TB-500. Listing three mechanisms does not test the mixture. [1] [2] [3]
Different ingredients. Different evidence.
GHK-Cu has cell-culture research. BPC-157 has tendon and injury experiments. TB-500 also has naming problems: evidence on full-length thymosin beta-four cannot simply be reassigned to a fragment. [1] [2] [3]
Blend-specific trials required
Combining substances introduces new questions about interactions, stability and safety. Separate ingredient studies cannot show that the blend improves skin or recovery in people. [3] [4]
No synergy or treatment claim
For an evidence-led explanation, ask for the exact formulation and controlled human outcomes. A memorable stack name is not a clinical result. [3]
Sources and context
These linked sources support the evidence distinctions in this short overview. This is not a systematic review, endorsement or treatment recommendation.
- Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex GHK-Cu →Primary cell-culture study
- The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration →Primary rat tendon explant and tendon-cell study
- FDA Pharmacy Compounding Advisory Committee briefing: TB-500-related bulk drug substances →US regulator technical identity and evidence assessment; July 2026
- FDA: Certain bulk drug substances that may present significant safety risks →US regulator; route-specific safety assessment, not a universal ban or approval list
